Danaher is trading up 5% at $206.24, extending a multi-session rally following strong Q2 results and the earlier-than-expected completion of its Masimo acquisition.
- Investors are encouraged by raised full-year 2026 EPS guidance and anticipated synergies from the Masimo integration.
- The move is further supported by improving life sciences momentum and broad strength in healthcare stocks as money rotates into the sector.